

Caprihans India Limited

May 29, 2024

Facilities/Instruments	Amount (₹ crore)	Rating ¹	Rating Action
Long Term Bank Facilities	620.00	CARE BB-; Stable; ISSUER NOT COOPERATING*	Rating continues to remain under ISSUER NOT COOPERATING category and Revised from CARE BB; Stable;
Long Term / Short Term Bank Facilities	1.00	CARE BB-; Stable / CARE A4; ISSUER NOT COOPERATING*	Rating continues to remain under ISSUER NOT COOPERATING category and Revised from CARE BB; Stable / CARE A4+;
Short Term Bank Facilities	51.75	CARE A4; ISSUER NOT COOPERATING*	Rating continues to remain under ISSUER NOT COOPERATING category and Revised from CARE A4+;

Details of instruments/facilities in Annexure-1.

*Issuer did not cooperate; based on best available information.

Rationale and key rating drivers

CARE Ratings Ltd. had, vide its press release dated May 23, 2024, placed the rating(s) of Caprihans India Limited (CIL) under the 'issuer non-cooperating' category as CIL had not paid the surveillance fees for the rating exercise as agreed to in its Rating Agreement. In line with the extant SEBI guidelines, CARE Ratings Ltd. has reviewed the rating on the basis of the best available information which however, in CARE Ratings Ltd.'s opinion is not sufficient to arrive at a fair rating.

Users of this rating (including investors, lenders and the public at large) are hence requested to exercise caution while using the above rating(s).

While revising the ratings, CARE Ratings has noted the weaker-than-expected operating performance of the company in Q4 and full year FY24. CIL reported a 25% YoY decline in its total operating income to Rs. 704.19 crores in FY24 against Rs. 939.10 crores in FY23. Further, the company reported net loss of Rs. 51.6 crores in FY24 as compared to profit after tax of Rs. 71.76 crores in FY23 (after considering exceptional gain of Rs. 126.82 crores). The ratings remain constrained by the modest operating margin, leveraged capital structure following the acquisition, the susceptibility of its revenue and profitability to government regulations, volatility in crude oil prices and foreign exchange rates. However, the above weaknesses are partially offset by strengths derived from its established track record in the packaging industry.

Analytical approach: Standalone

Detailed description of the key rating drivers:

At the time of last rating on May 23, 2024, the following were the rating strengths and weaknesses (updated for the information available from Bombay stock exchange)

Key weaknesses

Subdued operating performance leading to PAT losses in FY24

CIL's total operating income has declined by ~25% on y-o-y basis and stood at Rs. 704.19 crores in FY24 as compared to Rs. 939.10 crores in FY23. Further, the company has reported net loss of Rs. 51.6 crores in FY24 as compared to profit after tax of Rs. 71.76 crores in FY23 (after considering exceptional gain of Rs. 126.82 crores)

Highly leveraged capital structure post-acquisition:

CIL, from a zero-debt company, has turned to be a highly leveraged entity with the acquisition of PPI unit from its holding company. The acquisition process was completed in March 2023 for a net consideration of Rs. 213.00 crores. The company took over the liabilities of Bilcare Ltd aggregating to Rs.620.00 crores and same was paid by availing bank borrowing. The total debt of the company majorly comprises term loans. The other debt components are public deposits, redeemable preference shares issued to the holding company, working capital facility and payables backed by LC. Moreover, the net worth of the company has turned negative at Rs. 288.49 crores as on Mar 31, 2023, post the acquisition of the operational asset, with negative capital reserve. The said net worth is excluding the revaluation reserve. The debt coverage indicator stood weak marked by interest coverage stood at 0.53x as on Mar 31, 2024

¹Complete definition of the ratings assigned are available at www.careedge.in and other CARE Ratings Ltd.'s publications

Susceptible to government regulations:

The pharmaceutical and food industry are major customers of the packaging industry. As both the user industries pertain to health and general well-being of the people at large, government regulations pertaining to packaging used in both these industries are very strictly implemented. Therefore, CIL's operation is susceptible to these regulatory risks, any unanticipated changes in which, could have a material impact on its financial risk profile.

Exposure to volatility in crude oil prices and foreign exchange rates

Polymer resin being a crude oil derivative, its prices are linked with crude oil prices. Additionally, these resins are largely imported, due to which its prices are also susceptible to the volatility in foreign exchange rates. CIL is able to revise prices with its pharmaceutical industry clients only with a lag of a few months. Thus, commodity price and foreign exchange fluctuation are significant risks to the profitability of the company.

Key strengths

Established track record of the company in the packaging industry

CIL has been in the business of flexible polyvinyl chloride (PVC) products since 1957 with an established track record of around six decades in the packaging industry. Over the years, the company has steadily expanded into decorative and industrial laminates, polystyrene sheets and plastic-corrugated sheets. It has diversified from flexible packaging products into manufacture of rigid PVC and polyvinylidene chloride (PVDC) films. The company caters to the packaging demand from pharmaceutical, fast-moving consumer goods (FMCG) and food industries. Besides, flexible PVC film and extruded products are used for a variety of other industrial applications.

Applicable criteria

[Definition of Default](#)

[Policy in respect of non-cooperation by issuers](#)

[Manufacturing Companies](#)

[Financial Ratios – Non financial Sector](#)

[Short Term Instruments](#)

About the company and industry

Industry Classification

Macro Economic Indicator	Sector	Industry	Basic Industry
Industrials	Capital Goods	Industrial Products	Plastic Products - Industrial

CIL was incorporated as a privately held company on April 11, 1946 and was listed on the Bombay Stock Exchange in 1976. The company is among the prominent players in rigid packaging. CIL's manufacturing units are located in Thane and Nasik, Maharashtra. The company is engaged in the processing of plastic polymers and manufactures rigid and flexible polyvinyl chloride (PVC) films by calendaring process poly vinylidene chloride (PVDC)-coated rigid PVC film and certain plastic products through extrusion process in India. CIL is presently promoted by Bilcare Mauritius Limited (holds 51% stake) and Bilcare Mauritius Limited is wholly owned subsidiary of Bilcare Limited (BIL). Bilcare Limited was into default from 2013 and was later taken into National Company Law Tribunal (NCLT) by its lenders in 2019. Later in 2023, BIL settled its dues in a one-time settlement process for which CIL leveraged its balance sheet to acquire the operating assets of Bilcare and BIL used these funds to repay its lenders.

Brief Financials (₹ crore)	March 31, 2022 (A)	March 31, 2023 (A)	March 31, 2024 (A)
Total operating income	799.09	939.10	704.19
PBILDT	59.17	62.81	43.99
PAT	-39.57	71.76	-51.62
Overall gearing (times)	-2.97	-2.98	NA
Interest coverage (times)	0.86	1.06	0.53

A: Audited NA: Not available; Note: 'the above results are latest financial results available'

Status of non-cooperation with previous CRA: Not Applicable

Any other information: Not Applicable

Rating history for the last three years: Annexure-2

Covenants of rated instrument / facility: Annexure-3

Complexity level of the various instruments rated: Annexure-4

Lender details: Annexure-5

Annexure-1: Details of instruments/facilities

Name of the Instrument	ISIN	Date of Issuance (DD-MM-YYYY)	Coupon Rate (%)	Maturity Date (DD-MM-YYYY)	Size of the Issue (₹ crore)	Rating Assigned along with Rating Outlook
Fund-based - LT-Term Loan		-	-	31-03-2031	570.00	CARE BB-; Stable; ISSUER NOT COOPERATING*
Fund-based - LT-Working Capital Limits		-	-	-	50.00	CARE BB-; Stable; ISSUER NOT COOPERATING*
Fund-based - LT/ ST-CC/Packing Credit		-	-	-	1.00	CARE BB-; Stable / CARE A4; ISSUER NOT COOPERATING*
Non-fund-based-Short Term		-	-	-	51.75	CARE A4; ISSUER NOT COOPERATING*

*Issuer did not cooperate; based on best available information.

Annexure-2: Rating history for the last three years

Sr. No.	Name of the Instrument/Bank Facilities	Current Ratings			Rating History			
		Type	Amount Outstanding (₹ crore)	Rating	Date(s) and Rating(s) assigned in 2024-2025	Date(s) and Rating(s) assigned in 2023-2024	Date(s) and Rating(s) assigned in 2022-2023	Date(s) and Rating(s) assigned in 2021-2022
1	Fund-based - LT/ ST-CC/Packing Credit	LT/ST	1.00	CARE BB-; Stable / CARE A4; ISSUER NOT COOPERATING*	1)CARE BB; Stable / CARE A4+; ISSUER NOT COOPERATING* (23-May-24)	1)CARE BB; Stable / CARE A4+ (09-Oct-23)	1)CARE BBB- / CARE A3 (RWN) (20-Jan-23) 2)CARE A-; Stable / CARE A2+ (05-Sep-22)	1)CARE A-; Stable / CARE A2+ (22-Mar-22) 2)CARE A-; Stable / CARE A2+ (07-Oct-21)
2	Non-fund-based-Short Term	ST	51.75	CARE A4; ISSUER NOT	1)CARE A4+; ISSUER NOT	1)CARE A4+	1)CARE A3 (RWN)	1)CARE A2+

				COOPERATING *	COOPERATING * (23-May-24)	(09-Oct-23)	(20-Jan-23)	(22-Mar-22)
							2)CARE A2+ (05-Sep-22)	2)CARE A2+ (07-Oct-21)
3	Fund-based - LT-Term Loan	LT	570.00	CARE BB-; Stable; ISSUER NOT COOPERATING *	1)CARE BB; Stable; ISSUER NOT COOPERATING * (23-May-24)	1)CARE BB; Stable (09-Oct-23)	1)CARE BBB- (RWN) (20-Jan-23)	-
4	Fund-based - LT-Working Capital Limits	LT	50.00	CARE BB-; Stable; ISSUER NOT COOPERATING *	1)CARE BB; Stable; ISSUER NOT COOPERATING * (23-May-24)	1)CARE BB; Stable (09-Oct-23)	1)CARE BBB- (RWN) (20-Jan-23)	-

*Issuer did not cooperate; based on best available information.

LT: Long term; ST: Short term; LT/ST: Long term/Short term

Annexure-3: Detailed explanation of the covenants of the rated instruments/facilities: Not Applicable

Annexure-4: Complexity level of the various instruments rated

Sr. No.	Name of the Instrument	Complexity Level
1	Fund-based - LT-Term Loan	Simple
2	Fund-based - LT-Working Capital Limits	Simple
3	Fund-based - LT/ ST-CC/Packing Credit	Simple
4	Non-fund-based-Short Term	Simple

Annexure-5: Lender details

To view the lender wise details of bank facilities please [click here](#)

Note on the complexity levels of the rated instruments: CARE Ratings has classified instruments rated by it on the basis of complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for any clarifications.

Contact us

<p>Media Contact</p> <p>Mradul Mishra Director CARE Ratings Limited Phone: +91-22-6754 3596 E-mail: mradul.mishra@careedge.in</p> <p>Relationship Contact</p> <p>Saikat Roy Senior Director CARE Ratings Limited Phone: 91 22 6754 3404 E-mail: saikat.roy@careedge.in</p>	<p>Analytical Contacts</p> <p>Sudarshan Shreenivas Director CARE Ratings Limited Phone: 912267543566 E-mail: sudarshan.shreenivas@careedge.in</p> <p>Raunak Modi Assistant Director CARE Ratings Limited Phone: 912267543537 E-mail: Raunak.modi@careedge.in</p> <p>Smith Jain Analyst CARE Ratings Limited E-mail: smith.jain@careedge.in</p>
---	---

About us:

Established in 1993, CARE Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the RBI. With an equitable position in the Indian capital market, CARE Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CARE Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CARE Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit.

Disclaimer:

The ratings issued by CARE Ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse, or recall the concerned bank facilities or to buy, sell, or hold any security. These ratings do not convey suitability or price for the investor. The agency does not constitute an audit on the rated entity. CARE Ratings has based its ratings/outlook based on information obtained from reliable and credible sources. CARE Ratings does not, however, guarantee the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE Ratings have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE Ratings or its subsidiaries/associates may also be involved with other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating/outlook assigned by CARE Ratings is, inter-alia, based on the capital deployed by the partners/proprietors and the current financial strength of the firm. The ratings/outlook may change in case of withdrawal of capital, or the unsecured loans brought in by the partners/proprietors in addition to the financial performance and other relevant factors. CARE Ratings is not responsible for any errors and states that it has no financial liability whatsoever to the users of the ratings of CARE Ratings. The ratings of CARE Ratings do not factor in any rating-related trigger clauses as per the terms of the facilities/instruments, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and triggered, the ratings may see volatility and sharp downgrades.

**For the detailed Rationale Report and subscription information,
please visit www.careedge.in**